LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San…
News
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
- Doctors identify brain abnormalities in Cuba attack patients
But acoustic waves have never been shown to alter the brain's white matter tracts, said Elisa Konofagou, a biomedical engineering professor at Columbia University who is not involved in the government's investigation. "I would be very surprised," Konofagou said, adding that ultrasound in the…
- Galectin plunges on NASH cirrhosis midstage miss
It is the standard of care to look for varices in these patients, said principal investigator Stephen Harrison, M.D., medical director of Pinnacle Clinical Research in San Antonio. Therefore, this existing paradigm may be used to identify the patients without varices, who would benefit from this…
- San Antonio manufacturing sector makes a $40.5 billion economic impact
Butler and Stefl said it is difficult to determine San Antonio's largest economic sector because they study the sectors in different years. For 2015, the health care and biosciences sector's economic impact was reported at $37 billion, but it now might be about the same as manufacturing as the…
- Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure
Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm's Phase 2b ... medical director of Pinnacle Clinical Research in San Antonio, Texas, and visiting professor of medicine at the University of Oxford, United Kingdom.